TESA LINSTAD: Open Payments
NPI 1952868713 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,427 in 65 payments from 19 companies in 2025. Trend: 2023 $2,258 · 2024 $2,770 · 2025 $1,427
Food & beverage: $1,427
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $378 |
| Alexion Pharmaceuticals, Inc. | 3 | $155 |
| PFIZER INC. | 18 | $146 |
| Eisai Inc. | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 1 | $117 |
| Novartis Pharmaceuticals Corporation | 2 | $75 |
| Teva Pharmaceuticals USA, Inc. | 2 | $59 |
| Neurelis, Inc. | 2 | $55 |
| UCB, Inc. | 2 | $54 |
| SK Life Science, Inc. | 2 | $41 |
Products named: QULIPTA, ULTOMIRIS, NURTEC ODT, Leqembi, AIRSUPRA, UBRELVY, KESIMPTA, AUSTEDO XR.
Industry payments across WA — which companies pay providers there.
